Singapore markets close in 4 hours 14 minutes

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4400+0.0600 (+1.78%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5148.87M
Enterprise value 379.39M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/sales (ttm)41.41
Price/book (mrq)2.28
Enterprise value/revenue 322.08
Enterprise value/EBITDA 7-1.25

Trading information

Stock price history

Beta (5Y monthly) 1.85
52-week change 3-50.94%
S&P500 52-week change 333.58%
52-week high 37.5500
52-week low 32.0800
50-day moving average 33.1332
200-day moving average 33.2456

Share statistics

Avg vol (3-month) 3526.42k
Avg vol (10-day) 3583.04k
Shares outstanding 543.28M
Implied shares outstanding 6N/A
Float 828.03M
% held by insiders 113.74%
% held by institutions 158.47%
Shares short (14 Sep 2021) 41.19M
Short ratio (14 Sep 2021) 44.27
Short % of float (14 Sep 2021) 43.31%
Short % of shares outstanding (14 Sep 2021) 42.74%
Shares short (prior month 12 Aug 2021) 41.29M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)-1,803.89%

Management effectiveness

Return on assets (ttm)-39.78%
Return on equity (ttm)-102.98%

Income statement

Revenue (ttm)3.6M
Revenue per share (ttm)0.11
Quarterly revenue growth (yoy)300.50%
Gross profit (ttm)-46.42M
EBITDA -63.42M
Net income avi to common (ttm)-67.62M
Diluted EPS (ttm)-1.9900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)70.39M
Total cash per share (mrq)1.63
Total debt (mrq)3.51M
Total debt/equity (mrq)5.38
Current ratio (mrq)6.95
Book value per share (mrq)1.51

Cash flow statement

Operating cash flow (ttm)-49.05M
Levered free cash flow (ttm)-29.34M